NTRA.O (NTRA.O) News
Follow NTRA.O (NTRA.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 3 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Natera, TransCode Therapeutics partner on Phase 2a colorectal cancer trial enrollment using Signatera MRD test
Natera entered a strategic collaboration with TransCode Therapeutics to support enrollment in a Phase 2a colorectal cancer trial. Signatera MRD testing will be used to identify eligible patients who remain MRD-positive a
NEWS | Oct 13, 2026, 11:35 AM UTC
H
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX — MC138 in Colorectal Cancer
For best results when printing this announcement, please click on link below: Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer TransCode will use Signatera™ to identify
REGULATION | Oct 13, 2026, 11:31 AM UTC
M
Natera enrolls first patients in Signatera-guided melanoma trial
The study is a randomized melanoma trial using Signatera to guide early immunotherapy escalation in advanced or metastatic patients with persistent molecular residual disease despite initial treatment; results have not b
EQUITY | Oct 07, 2026, 12:03 PM UTC